Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in children aged 2 to under 6 years with uncontrolled asthma or recurrent severe asthmatic wheeze
NL-OMON59544Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Dupilumab with Placebo (2 arms). Primary endpoints: Annualized rate of severe asthma exacerbations and Safety and tolerability. Started Feb 2025; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON59544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59544.